Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.06. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
23.05. | Apimeds Pharmaceuticals US, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
20.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
20.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 493 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
12.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 113 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen | |
APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
09.05. | Apimeds Pharmaceuticals starts trading at $4 per share in line with IPO pricing | 1 | Investing.com | ||
09.05. | Apimeds Pharmaceuticals startet Handel bei 4 US-Dollar je Aktie gemäß Börsengang-Preis | 2 | Investing.com Deutsch | ||
09.05. | Inflammation drug developer Apimeds Pharmaceuticals US prices IPO at $4.00, the low end of the range | 3 | Renaissance Capital | ||
05.05. | IPO Roundup: American Integrity Insurance, Apimeds Pharmaceuticals and more | 1 | Seeking Alpha | ||
02.05. | Apimeds Pharmaceuticals US, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
15.04. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
15.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.03. | Preview: Apimeds Pharmaceuticals Us, Inc Set To IPO Tomorrow | 20 | Benzinga.com | ||
03.03. | Apimeds Pharmaceuticals US, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
20.02. | Apimeds Pharmaceuticals Us, Inc To Start Trading Tomorrow | 1 | Benzinga.com | ||
06.02. | Apimeds Pharmaceuticals US, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
29.01. | Inflammation biotech Apimeds Pharmaceuticals ups deal size by 74% ahead of $20 million IPO | 3 | Renaissance Capital | ||
29.01. | Apimeds Pharmaceuticals US, Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders |
FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |